Based on the key indicators related to Adaptimmune Therapeutics' liquidity, profitability, solvency, and operating efficiency, Adaptimmune Therapeutics Plc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Adaptimmune Therapeutics' Property Plant And Equipment Gross is relatively stable compared to the past year. As of 11/29/2024, Total Current Assets is likely to grow to about 229 M, while Total Current Liabilities is likely to drop slightly above 44.6 M. Key indicators impacting Adaptimmune Therapeutics' financial strength include:
Investors should never underestimate Adaptimmune Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Adaptimmune Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Adaptimmune Therapeutics Plc.
Net Income
(119.56 Million)
Adaptimmune
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Investments
Total Cashflows From Investing Activities
Change To Account Receivables
Change To Operating Activities
Change To Netincome
Change To Liabilities
Other Cashflows From Investing Activities
Change To Inventory
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Short Long Term Debt Total
Common Stock Shares Outstanding
Short Term Debt
Property Plant Equipment
Net Tangible Assets
Non Currrent Assets Other
Short Term Investments
Other Liab
Current Deferred Revenue
Inventory
Intangible Assets
Capital Surpluse
Retained Earnings Total Equity
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Total Revenue
Gross Profit
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Tax Provision
Interest Income
Net Interest Income
Non Operating Income Net Other
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Adaptimmune Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Adaptimmune Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Adaptimmune Therapeutics' assets may result in an increase in income on the income statement.
Adaptimmune Therapeutics competes with Stoke Therapeutics, Black Diamond, Mereo BioPharma, Pieris Pharmaceuticals, and PDS Biotechnology. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. Adaptimmune Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 494 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Adaptimmune Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what Adaptimmune Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Adaptimmune Therapeutics's current stock value. Our valuation model uses many indicators to compare Adaptimmune Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adaptimmune Therapeutics competition to find correlations between indicators driving Adaptimmune Therapeutics's intrinsic value. More Info.
Adaptimmune Therapeutics Plc is rated below average in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Adaptimmune Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Adaptimmune Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Adaptimmune Therapeutics Systematic Risk
Adaptimmune Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Adaptimmune Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Adaptimmune Therapeutics correlated with the market. If Beta is less than 0 Adaptimmune Therapeutics generally moves in the opposite direction as compared to the market. If Adaptimmune Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Adaptimmune Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Adaptimmune Therapeutics is generally in the same direction as the market. If Beta > 1 Adaptimmune Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Adaptimmune Therapeutics Thematic Clasifications
Adaptimmune Therapeutics Plc is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Today, most investors in Adaptimmune Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adaptimmune Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Adaptimmune Therapeutics growth as a starting point in their analysis.
Adaptimmune Therapeutics November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Adaptimmune Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Adaptimmune Therapeutics Plc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Adaptimmune Therapeutics Plc based on widely used predictive technical indicators. In general, we focus on analyzing Adaptimmune Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Adaptimmune Therapeutics's daily price indicators and compare them against related drivers.
When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.